Ophthalmology Specialist Assoc. Dr. Okan Toygar said, “During the pandemic period, patients should follow the rules of mask, distance and cleanliness and continue their follow-up and treatment without interruption.”
“VISION OF THE CENTER IS DECREASING”
Stating that yellow spot disease is caused by the structural defect of the part that provides vision in the back of the eye, Assoc. Dr. Toygar said, “In those with this disease, central vision decreases, peripheral vision is preserved. Patients see the images blurred in the middle, but the edges are normal. Straight lines such as electric poles, doors, windows edges, lines of writings appear wavy. There are two types of the disease, dry and wet type. Dry type is seen at a rate of 90% and wet type is seen at a rate of 10% .But early diagnosis in wet type is more important in terms of causing vision loss. The disease progresses faster than the dry type, with sudden vision loss, color vision and contrast sensitivity are deteriorated. “it causes vision loss as a result of bleeding in the new vessels formed in the retina and macula over time.”
DIAGNOSIS IN YELLOW SPOT DISEASE
Emphasizing the importance of early diagnosis in the treatment of the disease, Assoc. Dr. Toygar “Early diagnosis and early treatment are of great importance during the disease process. Because with current treatments, existing vision loss is mostly irreversible, but its progression can be stopped. For early diagnosis, you need to have your eyes checked regularly. In addition to a routine examination in which visual acuity is evaluated during eye examination, a comprehensive examination. Retinal examination and, when necessary, FFA (eye angiography) and OCT (optical coherence tomography) examinations are performed. “
Assoc. Dr. Okan Toygar, giving information about the treatment methods of Yellow Spot disease “It can be said that vitamin supplements and drugs with some antioxidant properties can slow down the course of the disease. There is no treatment method. Intraocular drug injections are a method that has been used for about 15 years. VEGF effective agents (Avastin / Altuzan, Lucentis or Eylea) are administered. In the first 3 months of treatment, an injection is made once a month, and then, if the lesion is thought to be still active during the 6-week controls, reinjection is performed as needed.